All sponsors

NovelMed Therapeutics

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-30
RECRUITING0
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO88%

Delay Index: of 8 active trials registered more than a year ago, 7 have moved their primary completion (readout) date by more than 6 months since first registration (median +52.0 months). See all sponsors →

Open NovelMed Therapeutics on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
NM8074
NCT05646524
P2Not yet recruitingParoxysmal Nocturnal Hemoglobinuria122027-08 (+42 mo)
NM8074
NCT05731050
P2Not yet recruitingPNH - Paroxysmal Nocturnal Hemoglobinuria62027-09 (+13 mo)
NM8074
NCT06226662
P2Not yet recruitingAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis122027-10 (+12 mo)
NM8074
NCT06887738
P2Not yet recruitingDermatomyositis82027-11
NM8074
NCT05646563
P2Not yet recruitingParoxysmal Nocturnal Hemoglobinuria122029-07 (+65 mo)
NM8074
NCT05647811
P1/2Not yet recruitingC3 Glomerulopathy182029-08 (+60 mo)
NM8074
NCT05684159
P2Not yet recruitingaHUS - Atypical Hemolytic Uremic Syndrome122030-04 (+56 mo)
NM8074
NCT06454110
P2Not yet recruitingIgA Nephropathy102030-12 (+52 mo)